Article · 10 Sep 2026
EditorialPublished 2013
Cost-effectiveness Considerations of Individualized Cancer Chemotherapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The running cost for clinical cancer treatment has risen dramatically. It is a huge burden to government fiscal budgets and cancer patients’ medical expenditure. Previously, we often create new drug and methodology of high cost and waste human resources for development of many less effects and expensive anticancer drugs or other sophisticated methodologies. These efforts will greatly increase therapeutic costs. Now some countries, such as USA or Japan, are overburden with high expense of medical resources in human diagnosis and therapy, especially for human cancer therapy. One of the major obstacles to controlling cancer growth and metastases is the inappropriate use of anticancer drugs. Treatment using individualized cancer chemotherapy (ICC) has been attracting increasing attention and will continue to show beneficial outcomes in the future. Increasing efforts to develop ICC strategies are generally paralleled with rising fee of diagnostic and prediction of drug responses and expense of anticancer drugs. Systematic evaluation of the relationship between the running costs and benefits of ICC is crucial for updating the ICC systems and making it available in the long run. In this editorial, we address and discuss this matter from different angels.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Advances in Pharmacoepidemiology and Drug Safety.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAdvances in Pharmacoepidemiology and Drug Safety
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Da-Yong Lu”
- BylineArticles whose byline prints “Ting-Ren Lu”
- BylineArticles whose byline prints “Hong-Ying Wu”

